10-Dec-2025
Broadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to Alcon
Business Wire (Thu, 11-Dec 7:00 AM ET)
Alcon’s Challenging Outlook: Sell Rating Amid Market Slowdowns and Overvaluation Concerns
TipRanks (Thu, 11-Dec 6:46 AM ET)
STAAR Surgical holder Yunqi Capital still against sale to Alcon
Seeking Alpha News (Wed, 10-Dec 10:08 AM ET)
Yunqi Capital Comments on STAAR Surgical's Go-Shop Process and Alcon's Revised Offer
Business Wire (Wed, 10-Dec 7:05 AM ET)
STAAR Surgical jumps after Alcon raises offer to $30.75/share in cash (update)
Seeking Alpha News (Tue, 9-Dec 1:13 PM ET)
Broadwood Partners Responds to Alcon's Increase to Proposed Acquisition Price of STAAR Surgical
Business Wire (Tue, 9-Dec 12:39 PM ET)
STAAR Surgical jumps after Alcon raises offer to $30.75/share in cash
Seeking Alpha News (Tue, 9-Dec 9:06 AM ET)
Alcon Announces Amended Merger Agreement with STAAR Surgical
Business Wire (Tue, 9-Dec 8:30 AM ET)
Business Wire (Mon, 8-Dec 1:28 PM ET)
Business Wire (Mon, 8-Dec 8:16 AM ET)
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Alcon trades on the NYSE stock market under the symbol ALC.
As of December 10, 2025, ALC stock price climbed to $80.21 with 1,453,747 million shares trading.
ALC has a beta of 0.80, meaning it tends to be less sensitive to market movements. ALC has a correlation of 0.27 to the broad based SPY ETF.
ALC has a market cap of $39.67 billion. This is considered a Large Cap stock.
Last quarter Alcon reported $3 billion in Revenue and $.79 earnings per share. This fell short of revenue expectation by $-5 million and missed earnings estimates by -$.03.
In the last 3 years, ALC traded as high as $101.10 and as low as $63.78.
The top ETF exchange traded funds that ALC belongs to (by Net Assets): EQTY, DFIV, DFAI, DFIC, DFAX.
ALC has underperformed the market in the last year with a return of -6.2%, while the SPY ETF gained +15.3%. In the last 3 month period, ALC fell short of the market, returning +3.0%, while SPY returned +5.7%. However, in the most recent 2 weeks ALC has outperformed the stock market by returning +1.3%, while SPY returned +1.2%.
ALC support price is $77.43 and resistance is $79.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALC shares will trade within this expected range on the day.